GSK 219867 GSK4527226 (Phase 2)

Back to Drug Development Trials
Drug Development Trials

About the trial

WA only

GSK4527226 is a monoclonal antibody that binds to sortilin, a transmembrane receptor that is a regulator of progranulin (PGRN). PGRN is a secreted protein that is expressed in the brain and is associated with the regulation of lysosomal function and neuroinflammation in Alzheimer’s disease. GSK4527226 has been shown to increase PGRN and hopes to reduce the decline in neurological function in Alzheimer’s disease patients.

Who can be involved:

  • Male or female, aged 50 – 85 years inclusive, at the time of informed consent
  • Must be diagnosed with mild cognitive impairment (MCI) or mild Alzheimer’s disease
  • Have an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • Visits: Every month for 18 months
  • 24 months study duration including screening and follow-up periods
  • IV infusion once a month
  • Must be able to tolerate MRI and PET scans
  • 33% chance of receiving a placebo

Additional info:

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email:

* Please note that participants in this study may have a chance of being placed on a placebo medication